Avalo Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Avalo Therapeutics, Inc. (AVTX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-35.13-31.54-41.66-84.38-63.50-16.07
Depreciation & Amortization0.171.990.172.451.843.99
Deferred Income Tax0.110.010.030.020.000.02
Stock Based Compensation5.853.487.558.176.790.00
Change in Working Capital-4.71-9.32-0.062.91-4.24-0.89
Change in Accounts Receivable-0.480.001.061.12-0.680.00
Change in Inventory0.000.020.02-0.040.020.00
Change in Accounts Payable-0.16-2.44-0.490.800.100.00
Change in Other Working Capital-4.071.83-0.740.79-4.160.00
Other Operating Activities-15.358.185.868.1325.362.81
Net Cash from Operating Activities-49.06-30.68-26.75-70.89-40.54-19.13
Investing Activities
Capital Expenditures0.000.16-0.100.110.060.26
Acquisitions0.360.000.000.0012.843.96
Purchases of Investments0.000.000.000.0012.840.00
Sales/Maturities of Investments0.000.000.000.00-1.64-5.15
Other Investing Activities0.000.000.000.00-1.64-1.01
Net Cash from Investing Activities0.36-0.13-0.10-0.1111.13-0.44
Financing Activities
Debt Repayment0.00-21.24-14.810.000.00-0.26
Common Stock Issued115.630.070.1129.4139.6312.90
Common Stock Repurchased0.000.00-14.810.00-0.090.00
Other Financing Activities60.2232.470.0339.705.16-0.08
Net Cash from Financing Activities175.8525.04-14.70106.7644.7812.56
Summary
Net Change in Cash127.15-5.77-41.5535.7615.38-7.02
Cash at Beginning of Period7.5513.3254.8619.113.7310.75
Cash at End of Period134.707.5513.3254.8619.113.73
Free Cash Flow-49.06-30.81-26.85-71.01-40.60-19.40
Supplemental Disclosures
Interest Paid0.001.932.931.590.001.05
Income Taxes Paid0.000.000.000.000.471.80